Nexus Letter for Gout Secondary to Hypertension Medication (2026)

The Secondary Pathway: Medication-Induced Gout

Under 38 CFR 3.310, a condition that is proximately caused or aggravated by a service-connected disability is eligible for secondary service connection. The VA has long recognized that medications prescribed to treat a service-connected disability fall within this pathway. When a medication causes a new condition, that condition can itself be granted service connection as secondary to the underlying primary disability.

Hypertension is one of the most common service-connected conditions among veterans — whether granted directly, presumptively under the PACT Act for certain exposure cohorts, or as secondary to PTSD or other primary conditions. Once hypertension is service-connected, the medication regimen used to control it becomes part of the medical-legal landscape for secondary claims.

Gout is the prototypical medication-induced secondary claim from antihypertensive therapy. The link between thiazide diuretics and hyperuricemia has been documented in clinical medicine for decades. When a veteran with service-connected hypertension develops gout after starting an antihypertensive medication, the secondary pathway is well supported in the medical literature.

Pharmacological Mechanism

Gout is caused by deposition of monosodium urate crystals in joints and soft tissues. The deposition occurs when serum uric acid exceeds the solubility threshold — generally above 6.8 mg/dL. Several mechanisms can raise serum urate: increased production (purine intake, cellular turnover) and decreased excretion. The vast majority of gout cases — roughly 90% — are driven by reduced renal excretion of uric acid.

Thiazide Diuretics

Thiazide diuretics including hydrochlorothiazide (HCTZ), chlorthalidone, and indapamide reduce renal uric acid excretion through two mechanisms. First, they cause mild volume contraction, which enhances proximal tubular reabsorption of uric acid along with sodium. Second, they directly inhibit secretion of uric acid in the distal nephron. The net effect is hyperuricemia within weeks of initiating therapy, with peak serum urate elevation typically occurring at therapeutic doses of 25 mg or higher.

Loop Diuretics

Loop diuretics such as furosemide and torsemide raise serum uric acid through similar volume-contraction and tubular-handling mechanisms. The effect is generally smaller per dose than thiazides but is dose-dependent and clinically meaningful in patients receiving sustained therapy.

Other Antihypertensives

Beta blockers (atenolol, metoprolol) and ACE inhibitors (lisinopril, enalapril) have a smaller association with hyperuricemia. Angiotensin receptor blockers vary by molecule: losartan has uricosuric properties and tends to lower serum urate, while other ARBs are neutral. Calcium channel blockers are generally neutral.

Which Antihypertensives Are Implicated

• Hydrochlorothiazide (HCTZ) — The most commonly prescribed thiazide. Strongly implicated in medication-induced hyperuricemia and gout, particularly at doses of 25 mg or above.
• Chlorthalidone — Longer half-life than HCTZ and similar uric-acid effects. Often used in combination antihypertensives.
• Indapamide — A thiazide-like diuretic with similar uric-acid effects.
• Furosemide (Lasix) — Loop diuretic. Raises serum urate dose-dependently.
• Torsemide — Loop diuretic with similar effects.
• Combination products — Many fixed-dose antihypertensives contain a thiazide component (lisinopril/HCTZ, losartan/HCTZ, valsartan/HCTZ). Veterans on these combinations are receiving a thiazide even if they describe their medication only by the brand name.

A thorough nexus letter identifies the specific medication, the dose, and the duration. Listing "blood pressure medication" without specificity weakens the medical argument.

How the VA Rates Gout (DC 5017)

Gout is rated by analogy under 38 CFR 4.71a Diagnostic Code 5017, which references the criteria for active rheumatoid arthritis under DC 5002. Ratings are based on the frequency and severity of incapacitating exacerbations and the degree of constitutional and functional impairment.

Under DC 5002, evaluations are assigned as follows:

• 100% — Constitutional manifestations associated with active joint involvement that are totally incapacitating.
• 60% — Less than 100%, with weight loss and anemia productive of severe impairment of health, or severely incapacitating exacerbations occurring four or more times a year, or a lesser number over prolonged periods.
• 40% — Symptom combinations productive of definite impairment of health objectively supported by examination findings, or incapacitating exacerbations occurring three or more times a year.
• 20% — One or two incapacitating exacerbations per year.

For chronic residuals such as limitation of motion or ankylosis, ratings are assigned under the appropriate diagnostic codes for the affected joints, but the higher evaluation under either the chronic residual ratings or the active-process rating — not both — is used.

What a Strong Nexus Letter Must Include

A defensible nexus letter for medication-induced gout secondary to antihypertensive therapy contains the following elements.

Identification of the Service-Connected Primary

The letter must name the primary service-connected condition (hypertension) and reference the rating decision or VA record that established service connection. Without an established primary, the secondary pathway has no anchor.

Specific Medication and Course

The letter must identify the antihypertensive medication by name (e.g., hydrochlorothiazide 25 mg daily), the prescription start date, the prescribing provider, and the duration of therapy. If multiple antihypertensives have been used, the timeline of each should be specified.

Pharmacological Mechanism

The opinion must explain why the medication causes gout. A brief, accurate description of the mechanism — reduced renal urate excretion via tubular handling and volume contraction — supports the medical rationale element that VA raters look for.

Temporal Correlation

The letter must document when gout symptoms first appeared in relation to medication initiation. Onset of acute podagra, tophi, or recurrent monoarthritis within months to a few years of starting a thiazide is consistent with medication causation.

Differential Considerations

A thorough letter briefly addresses alternative explanations — family history, dietary purine load, renal disease, alcohol intake — and explains why these are insufficient to outweigh the medication contribution. This strengthens the opinion against challenge.

The Required Legal Standard

The opinion must use the phrase "at least as likely as not" to indicate that the probability of causation or aggravation is 50% or greater. Anything less — "could be," "may have contributed," "possibly related" — does not satisfy the VA's evidentiary threshold.

Records-Based Review Statement

The letter must affirm that the physician reviewed the veteran's service treatment records, VA medical records, pharmacy records, and any private medical documentation. A records-based opinion carries substantially more weight than a letter written without records review.

Supporting Evidence

• Rating decision or VA letter establishing service connection for hypertension.
• Pharmacy records showing prescription history and fills of the antihypertensive medication.
• Serum uric acid levels before and after starting the medication, when available.
• Documentation of the first gout flare — emergency department visits, urgent care notes, primary care visits documenting acute monoarthritis with elevated uric acid.
• Joint aspiration results if synovial fluid analysis demonstrated monosodium urate crystals.
• Imaging showing tophi, joint erosion, or characteristic gouty changes.
• Treatment records for chronic urate-lowering therapy (allopurinol, febuxostat) and acute flare management (colchicine, NSAIDs, steroids).
• Statements documenting frequency and severity of incapacitating exacerbations to support DC 5017 rating tiers.

Common Mistakes

• Generic references to "blood pressure medication." The specific drug class and molecule matter. A letter that fails to identify the exact medication is weaker.
• Missing the mechanism. Without a pharmacological explanation for why the medication causes gout, the opinion lacks medical rationale.
• Ignoring the temporal pattern. A nexus letter that does not address when gout symptoms appeared relative to medication start cannot establish causation cleanly.
• Not addressing alternative causes. Adjudicators look for evidence that the physician considered and ruled out other explanations.
• Wrong legal standard. Letters using "possibly," "could be," or "may be" fall below the "at least as likely as not" threshold.
• No records review. An opinion written without reviewing the underlying records is given reduced evidentiary weight.
• Failure to claim aggravation. Even if a veteran had idiopathic gout before the medication, aggravation by the medication is a valid secondary pathway when properly documented.